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Cardiothoracic surgeons must become more involved in developing new technology
to improve patient care and further the specialty. Surgeons encounter unique
observational experiences in the operating room, which can provide a wellspring of
innovative ideas. However, to achieve true value of a clinical benefit, unique ideas
must be expanded, modeled, developed, and applied. Collaboration and a new way
of thinking for cardiothoracic surgeons must emerge to be effective in this arena.
With retrenchment of clinical revenues, project funding has focused increasingly on
industry, government, and private channels. Herein, both developmental pathways
and methods of funding new technologic ideas are examined.
In questions of science . . . . The authority of a thousand is not worth that humble
reasoning of a single individual.
—Galileo Galilei
Keeping Cardiothoracic Surgeons in the Game
Surgeons are experiencing increased challenges to improve patient care and service
efficiency with fewer complications in older patients with more complex conditions.
At the same time, oversight and “score card” reporting have broadened expectations
toward less surgical invasiveness, better cost containment, improved patient quality
of life, workforce optimization, increased patient comfort, fewer readmissions, and
more outpatient care. Concomitantly, patients have become cognizant that catheter-
based procedures are much less invasive than conventional surgery and that results
are improving rapidly. Our cardiology colleagues have fostered an explosive growth
in new techniques and devices for treating coronary artery disease, congenital heart
defects, peripheral vascular disease, and complex arrhythmias. Vascular surgeons
and cardiologists have developed effective stents for aorto-iliac, carotid, and renal
arterial lesions. In many centers aortic aneurysms are treated routinely with percu-
taneous endovascular grafting. Recently, Osterle1 predicted that in 10 years patients
undergoing an interventional procedure in “U.S. catheterization laboratories” would
jump from 800,000 to over 10 million yearly. Despite these advancing nonsurgical
therapies, many opportunities still exist for cardiothoracic surgeons.
To expand our specialty and in many instances remain in the game, cardiotho-
racic surgeons must develop imaginative technology that expands and extends our
capabilities toward completely new horizons. We must become involved in the
development and application of catheter-based therapy. A new breed of surgeon
must evolve to one comfortable with both catheter-based therapy and open proce-
dures. Over the next 50 years, the expansion of gene-based treatment for cardio-
vascular diseases seems nearly limitless, and surgeons must become integrated into
this evolution. Similarly, we must develop, improve, master, and teach truly less
invasive surgery through telesurgery using micromanipulation devices. To achieve
these goals, established cardiothoracic surgeons must encourage and support new
idea development. Moreover, we must teach younger investigators how to protect,
develop, and fund their ideas. Osterle closed his article by saying, “The next
generation of cardiologists and heart surgeons will likely share similar training
experiences . . . a new endovascular-cardiovascular specialist will likely emerge in
the process.”1 Our specialty must meet this challenge through innovation, imagina-
tion, and integration.
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The Innovation Imperative
Recently, Toby Cosgrove,2 in his 1999 Presidential address
to The American Association for Thoracic Surgery (AATS),
chided cardiothoracic surgeons to, “think anew and act
anew in clinical practice, education, research, and health
care delivery.” He stressed that, “At no time in human
history has the potential been greater for translating biologic
knowledge and technical capability into powerful tools for
preventing and treating disease.” He was speaking of trans-
lational research in which biologic concepts are expanded
to clinical applications through planned development and
clinical trials. Innovation is defined as the alteration of what
is established with the introduction of new elements to
develop a novel practice method. It requires an entirely new
way of thinking about old problems, as well as discovering
new ones to solve.3 Innovation has been a touchstone for
progress in medicine and science over the centuries. Inno-
vative thinking is the first step to development of new ideas
in practice and technology. Surgeons must do more than just
“dust off” and reapply the term to current methods. We are
in another age of surgical discovery, similar to that of John
Hunter and Alfred Blalock, but one in which technologic
complexity has increased logarithmically in a shorter time
period. Advances in computer, electronic, engineering, and
information technology have catapulted ideas, impossible to
develop formerly, into routine clinical application.
In the late 15th century, Leonardo da Vinci cultivated
personal qualities that sculpted his ingenuity and became
the impetus for his inventions, discoveries, and art (Table
1).4 His quest for learning, willingness to embrace ambigu-
ity, benefiting from mistakes, and for experimentation are
familiar to every surgeon. These ideals, added to his pursuit
of a balance between logic and imagination as well as
sensory refinement, cultivation of ambidexterity, and an
understanding of biosystem interconnectivity, became the
wellspring of Leonardesque innovation. Many of these are
inherent in our surgical training programs and daily lives.
Ideas for developing new surgical technology may be
spawned in operating rooms, at the bedside, or even in odd
places, such as hardware or cooking stores. Although sparks
for imaginative ideas may emanate from simple observa-
tions, they must be cultivated to reach even potential value.
Cardiothoracic surgeons have always been creative, and
technology development seems natural.
Technology Evolution: Timing Is Important
In the past, cardiothoracic surgeons have been forward-
thinking innovators. The individual contributions of Nina
Braunwald (valves and biosurfaces), Alain Carpentier (bio-
prosthetic heart valves), Denton Cooley (new operations),
John Gibbon (cardiopulmonary perfusion), Michael De-
Bakey (vascular grafts), C. Walton Lillehei (congenital
heart surgery), Norman Shumway (transplantation), Albert
Starr (mechanical heart valves), and Magdi Yacoub (surgi-
cal immunology) typify this innovative spirit. However, for
their innovations to become a true advance in surgery, their
ideas had to be co-mingled with other contemporary tech-
nologic advances in other disciplines.
It is just as interesting to review failed early attempts to
develop complex surgical technology. Many of the prob-
lems in past eras had potential solutions, but other factors
prohibited development. In 1900, Payr5,6 published very
good ideas regarding blood vessel connectors. His magne-
sium rings were innovative and unique, providing everted
endothelial apposition and a stented opening. Why did this
device not develop? Recently, proximal aorto-graft connec-
tors have become very successful. Why have these worked
and why will graft-coronary anastomotic devices succeed?
Modern engineering concepts and new materials now en-
able avant garde developmental potential. New deformable
hybrid metals have geometric memory, which can affect
efficient, accurate deployment. Moreover, interactions be-
tween coagulation systems and conduit materials have been
defined better, and pharmacologic agents can inhibit inter-
fering coagulation cascades. Thus, Payr’s idea, which from
the start manifested great latent potential, waited 100 years
to become a practical development.
Similarly, Cutler and Beck7 fabricated a cardioscope
with the notion of examining and treating cardiac valvular
stenosis in beating hearts. Also, Sakakibara and associ-
ates,8,9 using an improved cardioscope, closed an atrial
septal defect and performed aortic valve commissurotomies.
These attempts never advanced to the next level because of
blood opacity, inferior optics, and light transmission imped-
iments. Today, we can stop the heart, look inside with
3-dimensional high-resolution cameras, and repair
valves.10,11 Moreover, echocardiographic techniques now
allow us experimentally to visualize and repair valves in
TABLE 1. Seven da Vinci principles: A guide for innovation
Curiosita´
Insatiable curiosity and quest for continuous learning.
Dimostrazione
Commitment to test knowledge through experience and to
learn from mistakes.
Sensazione
The continual refinement of the senses, especially sight, as a
means to improve experience.
Incertezza or Sufmato
Willingness to face and understand ambiguity, paradox, and
uncertainty.
Arte/Scienza
A balance between art, science, logic, and imagination.
Corporalita´
Cultivation of grace, ambidexterity, fitness, and poise.
Connessione
A recognition of the interconnections of all things and
phenomena.
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beating hearts. Cutler, Beck, and Sakakibara’s concepts
were well conceived but remained undeveloped because of
inadequate coapting technologies. As evidenced by the
space program, technologic advances in one field may beget
diverse developments in others. New ideas must be evalu-
ated in the context of other contemporary advances; they
can ripen more effectively by “pinging” against other inno-
vations. For surgical scientists today, many more support
options are available than in past eras, and these have
resulted in what really is a technology development “am-
plification factor” not seen previously.
Developing New Technology: The Matrix for
Success
The route to successful development of new technology is
paved with a heterogeneous matrix (Table 2), characterized
by many Leonardesque principles described earlier. Clearly,
there must be a clinical goal, and the development process
must be focused on this ultimate application. Re-engineer-
ing and/or redesign of an older idea, product, or application
may abbreviate the time to project success. Ideas can be
triggered in either a creative or mundane environment, but
they must be developed. The idea then must be “sold”
conceptually to someone who can help improve it, provide
funding for expansion, or who wants to own the idea.
Whatever the path, the ensuing steps are to re-engineer and
smooth the developing idea. This all has to be done before
the first attempts at clinical application are possible. Gen-
erally, a process similar to the one shown in Table 3 is
required to bring an idea to either clinical trials or full
application.
Surgeons should not hesitate to learn entirely new skills
and collaborate with diverse disciplines. During recent ad-
vances in catheter-stent technology, cardiologists gained a
great deal of experience by working with bioengineers and
cellular scientists. Most of us do not have the resources to
recruit experts in each area to our laboratories and must rely
heavily on interdisciplinary and industrial collaboration.
Many companies employ focused project scientists and
engineers with whom surgeons can work closely. Project
success can be enhanced through greater synergy between
diverse scientific interests and talents. For example, robotics
and angiogenesis seemingly have dissimilar applications;
however, robotic systems could become the springboard to
efficacious gene therapy by providing a facile epicardial
delivery system for angiogenic agents.
Translational research bridges the gap between basic
science studies and clinical applications. This is the area of
research that seemingly will become the most fruitful for
surgeons. Pre-clinical trials may include simulated human
environments, animal studies, cadavers, or ethical studies in
informed patients. Development activities are then focused
on application of these research and engineering techniques
to solve problems resulting in new devices, systems, mate-
rials, or procedures. Design relates to developing product
testing protocols, as well as models or prototype construc-
tion. Here, structural or process plans are developed, con-
ducted, and finalized by using either computational engi-
neering design capabilities or biologic modeling. Finally,
after the piece of new technology has been modeled, edu-
cational support must be developed to train surgeons, an-
cillary health practitioners, and research coordinators. Si-
multaneously, public education should be fostered to
provide better understanding of future product or device
application. Ideas must be expanded to this point before
serious clinical trials can begin evaluation. The Food and
Drug Administration (FDA) has specific standards regard-
ing new device/drug/product safety, efficacy, informed pa-
tient consent, and education of clinical trial participants.
Our institution has developed a robotic training center and
curriculum designed to provide didactic and technical ex-
perience for surgeons and their operative teams who wish to
begin robotic clinical trials.12
Technology Development Opportunities for
Cardiothoracic Surgeons
Today, more than ever, we have opportunities to sculpt our
technologic future in cardiothoracic surgery. Some ideas are
simple to develop, and others are difficult. Instrument de-
sign and modifications are usually the first innovation leap
for surgeons. Surgeons have the benefit of seeing first-hand
clinical applications that warrant development of new de-
vices and instruments. Many companies are pleased to work
TABLE 2. New technology development: The matrix for
success
• A clinical goal paramount
• Benefits and safety for patients paramount
• Scientific curiosity is key
• A historical subject review
• Develop an organized approach
• Prioritize and apply new concepts
• Re-engineer and re-apply
• Collaborate with different disciplines
• Learn new skills beyond training
• Collaborate with industry
TABLE 3. Idea to clinical application: The 10-point process
1. Idea
2. Intellectual property protection
3. Financing
4. Research
5. Laboratory and clinical trials
6. Peer journal publication
7. Design and redesign
8. Product development
9. Education and training
10. Clinical application
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with surgeons to perfect, re-engineer, or develop a new
instrument. For example, the Scanlan and Pilling families
have worked for years with surgeons to design, model, and
improve cardiovascular instrumentation. For the surgeon,
instrument design and clinical application are enjoyable and
intellectually rewarding. Moreover, these contributions are
well within the reach and time commitment of most sur-
geons. Intermediate areas of developmental difficulty in-
clude off-pump coronary surgery, surgical robotics, and
videoscopic cardiac surgery. Areas that require the most
expertise and collaboration are typified by fetal surgery,
blood conduit development, cellular restoration, valve tissue
engineering, and cardiac replacement pumps. Creation of
new surgical imaging techniques requires many more re-
sources, which become impossible without major industrial
collaboration. Table 4 lists some of the current opportunities
for academic and private cardiothoracic surgeons to develop
new technology. Securing appropriate collaborators early in
a zealous project is central to ultimate success.
Entrepreneurialism and Industrial Partnerships
For cardiac surgeons the term entrepreneurialism was dark-
ened temporarily because of the unbridled self-interest of a
few. Several business co-ventures ultimately became polit-
ical and ethical burdens to our specialty. This happened
when surgeons became involved in global marketing and
company finance well before clinical efficacy and risks were
established firmly. Device- and technique-related complica-
tions were minimized. At the same time, public advertising
on television, by hospitals, in airline clips, and in magazines
pushed this technology as a public consumer product. For a
while, a patient’s cardiac operation seemingly was not as
good as a neighbor’s unless specific commercial products
were used. Surgeons who denied complications, boasted of
unrealistic benefits, and invested in the financial success of
the company lost a great deal of peer credibility.
Despite these lessons, business integration with aca-
demic investigation can be done appropriately and can
provide economic stimulation for the development of labo-
ratories, centers, and departments, as well as hospitals and
universities. Many institutions have adopted “win-win” phi-
losophies and encourage entrepreneurialism with returns
through patents, royalties, and company equity. Tripartite
business alliances are being encouraged between institu-
tions, investigators, and industry. Surgeon investigators
must be aware of institutional policies, their intellectual
property rights, and ethical borders in these areas. Early
co-venturing during development is appropriate; however,
efficacy and safety should be established firmly before
advanced clinical trials are begun. I think it prudent to have
no financial interest in devices and applications in which the
investigator is involved clinically. Although this opinion is
not shared uniformly, it is the safest way to avoid public
scrutiny and maintain maximal objectivity. Challenges in
obtaining funding for new ideas have required many
projects to be supported by prior business successes. Uni-
versities and clinicians have become more reliant on each
other to provide a feedback mechanism to stimulate growth
in their “technology think-tanks.” Societal and institutional
returns are obvious—improved health care, positive public
relations, a premium faculty, and greater research funding.
Intellectual Property: Protecting Bright Ideas
It is imperative to protect intellectual property (IP) early in
the development process. One should document discoveries,
innovations, and ideas in a laboratory notebook with appro-
priate drawings. Entries must be signed by the investigator
and witnessed by another person. The notebook should be
kept in a safe place and entries should be copied periodi-
cally and mailed back to the investigator, postmarked and
unopened for safe filing. Surgeons must understand their IP
position before disclosures are made to industrial suitors or
collaborators. In some instances institutional and university
officers direct all IP activities. In this scenario the investi-
gator must discuss ideas with university officials first and
get permission to broker the idea. In other institutions the
innovator may act as his or her own agent and interface
independently with third parties developing the idea before
returning to the university for permission. Most universities
TABLE 4. Opportunities for new technology: Discovery and
innovation
• Anastomotic devices
• Atrial arrhythmia therapy
• Biocompatible materials
• Bioadhesives
• Cellular biology
Myocardial cellular restoration
Neo-endothelialization
Angiogenesis
Cellular redifferentiation
Natural vascular conduit modification
Inflammatory response modification
• Heart failure
Ventricular remodeling
Geometry altering devices
Mechanical support devices
• Heart valves
• Interventional catheter technology
Thoracic aortic stent grafts
Treatment of aortic dissections
• Perfusion technology
• Radiosurgery
Tumor radiofrequency ablation
Robot-focused tumor ablation
• Surgical robotics
Operative simulation
Navigation and positioning devices
Forced feedback
• Surgical optics and vision
• Tissue fixation devices
Editorials Chitwood
226 The Journal of Thoracic and Cardiovascular Surgery ● August 2002
ED
ITO
RIA
L
specify that a portion of the rewards be returned to the
school. The portion returned to the department, laboratory,
or individual should be negotiated and approved by univer-
sity technology transfer officers. Successful brokering can
provide optimal return funding needed to expand idea de-
velopment and design. One should negotiate with the de-
partment or university officials in advance of complete
disclosure. Moreover, it is beneficial to renegotiate agree-
ments when they remain too restrictive or provide too little
incentive. Individuals should read all institutional employ-
ment and confidentiality agreements in detail. No matter
what, it is important to review all university IP policies and
agreements and then discuss them with technology transfer
officers, university attorneys, and the departmental chair-
person. It is key to determine exactly who owns your IP
before discussing your ideas with anyone, no matter how
“hot” your ideas may seem. Casual public conversations can
threaten the primacy of your idea, as can any mention in a
publication. The best possible relationship with the institu-
tion should be sought and a spirit of full disclosure and
cooperation should be adopted, but only after the IP is
protected. For additional help, patent attorneys, technology
specialists, and experienced surgeons can help clarify spe-
cific situations.
Final protection of an idea, invention, or innovation must
be secured through the federal patent route. Clearly, inves-
tigators and institutions are in the strongest financial nego-
tiating position if the idea is developed fully and patented.
Most universities have excellent patent attorneys who are
helpful in this area. More independent individuals may have
opportunities to secure a private patent attorney in a specific
field. A Provisional Patent Application is usually the first
entry into the US Patent and Trademark Office (http://
www.uspto.gov/). This application provides a first to file
date, international protection, and 1 year to file a formal
application. Moreover, it is inexpensive and relatively sim-
ple to file; however, the idea is disclosed immediately to the
public. Investigators have but 1 year to file both a US and
international patent application. After this, the basic idea is
disclosed globally and no other IP protection exists. A
Non-provisional Patent Application requires full disclosure
of the idea or device, is protective internationally, and is
much more expensive to develop. A “utility patent” protects
the way an article is used and works and a “design patent”
protects the way an article looks. Some inventions may
require protection by both types of patents.
Valuation of IP
Who should negotiate the value of your IP and how is it
determined? When agents are retained to negotiate and
determine the value of technologic innovations, less work is
required by the investigator and more experience is gained.
However, the individual becomes more dependent on the
agent’s judgment and abilities. The investigator is actually
in a better position to determine value of his or her idea, but
negotiations will require much more personal effort. Expe-
rience in this area definitely places surgeon investigators in
a stronger negotiating position.
IP values depend on several issues. A completely novel
or new idea generally has more value than an improvement
of an existing device, method, or process but involves more
risk and investment by both the inventor and acquirer of the
idea. In determining the value of an idea, medical device
and equipment manufacturers must determine whether the
innovation adds significant value to their existing product
portfolio and long-term business strategy. New product
improvements often require further financial commitments
and technologic development, and manufacturers also will
factor in the costs to market and launch a final product to
determine the value of the new idea or improvement. Usu-
ally the product market already has been developed, and the
manufacturer’s hope to expand this opportunity is its incen-
tive to evaluate new ideas. Companies are willing to pay
royalties but shy away from giving equity. Small companies
or start-up ventures are more inclined to offer equity or
stock option incentives. The surgeon innovator and/or insti-
tution must determine the parameters for brokering their
idea to the greatest advantage. Greater individual diligence
on understanding the potential value of the idea gains the
inventor more respect from the company, speeds the eval-
uation process, and places the inventor in a stronger nego-
tiating position. When a completely new idea is developed,
IP value is difficult to establish because the market or
clinical use is not yet fully developed. Novel ideas, how-
ever, add true value to health care. Improving neurologic
safety in high-risk coronary patients using “no-clamp” prox-
imal vein graft–aortic anastomotic devices or atheroemboli
filtering cannulas exemplify the value gained.
Well-developed and well-protected ideas have the great-
est IP value and financial return. For unique ideas, economic
value can be difficult to determine because no comparative
measures exist. Thus, investigators should seek the advice
of experienced consultants, attorneys, and “good friends.”
They can help determine the latent value of an untested
product. If an idea can be developed into a company, much
more value and potential revenue exist. In this instance the
uniqueness precludes significant competition enhancing fi-
nancial value. Many universities now champion the devel-
opment of “spin-off companies” and invest in the further
product development, gaining an equity position. Investiga-
tors and institutions often need to garner outside investors
but must be aware of potential dilution of the equity posi-
tion. Exit strategies and acquisitions by another company
may be profitable, but generally original investigator control
is relinquished. If the idea results in a product and not
company development, a weaker IP position exists since
there is a great deal of competition. In the situation de-
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scribed, dilution by outside investors is less and exit strat-
egies generally relate to royalties and license agreements.
Here, there is a higher likelihood of achieving a continued
income stream with less risk and loss of product develop-
ment control.
Financing Technology Development
Technology development strategies today must include cre-
ative ways to finance expensive ventures. Clinical revenues
in cardiovascular surgery have fallen so sharply that this
source nearly has become irrelevant for research and devel-
opment. Also, traditional extramural granting agencies often
are not willing to finance development of new clinical
devices. The National Institutes of Health (NIH) and the
American Heart Association (AHA), formerly major
sources of funding for young and established cardiovascular
surgical investigators alike, have directed many of their
priorities toward nonsurgical areas. Conversely, industry
support has become an important new resource, helping
many worthy projects through engineering, patent applica-
tion, capital, and clinical study support. Clearly, recent
progress with vascular anastomotic devices, surgical robots,
cardiac remodeling techniques, tiny cardiac assist pumps,
endovascular grafts, bioadhesives, and off-pump instrumen-
tation have evolved from creative partnerships between
academic institutions, industry, and surgeons.
Today, more than ever, to fund development of new
ideas and technology, investigators cannot rely on single
sponsorship and must adopt a diversified strategy with mul-
tiple sources. My institution has relied on a combination of
financial resources to develop our surgical robotics pro-
gram. Diversification of a support profile for a laboratory or
investigator has many positives and some disadvantages.
The following financial sources are most commonly sought
today for medical device and pharmacologic technology
development.
University and institutional resources are less plentiful
than in past years because of state and federal budget cuts,
shrinking clinical reserves, increased expenses, and stifled
philanthropy. Most medical school deans and departmental
chairs enthusiastically support translational research and
technologic innovation; however, their financial resources
have dwindled because of falling clinical income and indi-
rect-cost rebate reductions by university systems. However,
in some institutions venture capital arms have been created
specifically to fund health care–related technology. More-
over, university foundations, established through fund rais-
ing campaigns and planned philanthropy, may be sources
for “starter” grants for good ideas, especially for young
investigators. Most university coffers are not prepared to
fund technology development in perpetuity and other
sources must be engaged.
Philanthropy may be directed to purchase capital equip-
ment, as well as provide naming opportunities of facilities
and laboratories. A cardiothoracic surgeon’s community
and university contacts may provide ideal opportunities for
financing idea development. As most extramural granting
agencies generally prefer not to provide funds for equip-
ment and facilities, direct philanthropy from grateful pa-
tients or industry is an important source for necessities
required to begin clinical and basic science research. Good
friends of the institution are becoming more helpful in this
area, and university contacts should try to minimize restric-
tions on these funds and broaden this venue for financing
new research and development.
Charitable trusts and private foundations often have a
scientific arm that is interested in health-related research.
Direct contact with these groups can be made by investiga-
tors or through institutional avenues. Available funds are
usually moderate in size and provide 1 to 3 years of support.
These resources are usually directed toward experimental
design and development rather than for significant salary,
capital, or facility support. Working with these groups is
particularly satisfying and many important contacts can be
established.
Extramural granting agencies such as the NIH and AHA
remain sources for funding focused projects and in some
instances fellowships for junior faculty and postdoctoral
candidates. The new National Institute for Biomedical Im-
aging and Bioengineering (http://www.nibib.nih.gov/) sup-
ports basic and applied research in biomedical imaging and
bioengineering for good ideas, design, development, trans-
lation, and application of new medical technology. This
agency is interested in funding multidisciplinary, collabo-
rative biomedical research efforts with a translational mo-
tive. Interested investigators should contact directors of
these programs for guidance. Requests for proposals (RFP)
are published on the above NIH Web site and should be
reviewed periodically.
Surgical specialty foundations are directed toward devel-
oping and funding young clinical and basic science inves-
tigators. These foundations have partnered with industry,
philanthropists, and in some instances governmental agen-
cies to fund and oversee peer-reviewed surgical research.
The Thoracic Surgery Foundation for Research and Educa-
tion (TSFRE) has been instrumental in funding young aca-
demic cardiothoracic surgeons, as well as residents. The
TSFRE and the National Heart, Lung, and Blood Institute
recently have jointly sponsored the Mentored Clinical Sci-
entist Development Award Program (MCSDA), which
promises to expand research abilities of young academic
cardiothoracic surgeons (http://www.tsfre.org/doc/5401).
This support extends for 5 years and is not renewable. The
American College of Surgeons and American Surgical As-
sociations also have time-limited grants for junior faculty
and resident research development. The AATS sponsors the
Robert E. Gross Research Scholarship (http://www.aats.org/
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doc/4926). Each of the above is very helpful during resi-
dency training, in the initial phases of a laboratory start-up,
or in an early surgical career. These are not designed to fund
established surgical investigator projects but to “jump start”
innovative young investigators. Specialty self-funding rep-
resents a major advance, which has been needed to develop
young innovative surgeons, who are the key in directing our
technologically driven future.
Angel investors may be interested in either co-funding or
purchasing an idea after it is initially developed and pro-
tected. Angel investors are usually individuals who put part
of their wealth in a specific project development. Investiga-
tors must be sure that they are working with qualified
investors with a credible track record. Surgeons who work
with angels should definitely seek the advice of attorneys or
specialty consultants. These individuals can help with due
diligence in determining the suitability of these investors.
Industry may want to buy either a developed idea or one
in its infancy. Also, industry may invest in the development
of the idea. Investment may be done to obtain a competitive
advantage over another product or company. Also, it can be
done to block competition and avoid brokering the idea to a
competitive company. For the investigator these sources
provide the least equity position of all partnerships; how-
ever, industry support may be a good financial route for idea
development. The innovator may lose control of the direc-
tion of his or her idea after a company gains a large part of
the development authority. In fact the company may table
the idea and stop development just to prevent competition
with a similar item already in their product line. In other
words, loss of control can result before negotiations are
complete without careful analysis and consultation.
Industry developers often look toward universities and
surgical departments to provide laboratory venues for prod-
uct development. Generally, these ideas have been pro-
tected, prototyped, and developed partially. Many private
and university laboratories have advanced technologic ca-
pabilities and can facilitate long-term experimental model-
ing. Such facilities provide ideal venues for product devel-
opment and maturation. Companies benefit from surgical
expertise and the reduced costs incurred through “out-sourc-
ing” of both facilities and technical personnel. Contractual
agreements should be made between the institution and
company before studies are begun. Institutions and labora-
tories can profit greatly from alliances with industry, and
these resources can be used to fund other projects. Also, this
venue provides greater opportunities to evaluate a specific
technology. Similarly, to educate surgeons in clinical trials
and some FDA approved technology, industry partners of-
ten provide institutional educational grants for training cen-
ters. Any training profits can be used to finance other
laboratory and developmental projects; however, care must
be taken when negotiating such agreements. Many compa-
nies will desire to restrict or control the use of competing
products in training facilities they have funded or support.
Institutions must weight these considerations against their
goals to maintain clinical objectivity.
Venture capital funds have been an important financial
source for development of new surgical technology. These
large resources are composed of multiple investors who
allow their agents to invest in projects that have a high
probability of successful development with large potential
economic returns. Individual investments are directed to-
ward reaping a profit for the investors, and the only moti-
vation is a return on investment. Thus, when an idea is
dependent completely on venture capital for development,
the investigator may easily lose direction to the dominant
equity group. In this scenario there is loss of autonomy, and
inventor/innovator longevity in the venture may be in jeop-
ardy. Surgeon investigators must realize this risk. However,
the potential returns to the institution or individual may be
great if the idea moves to a competitive and/or marketable
product with value and becomes a public company through
an initial public offering (IPO) or is acquired by another
company.
Clinical trials are rapidly becoming a major source of
program funding. The Duke Clinical Research Institute
(DCRI) typifies a well-organized effort directed toward
major cardiovascular clinical trials (http://www.dcri.duke-
.edu/). Government agencies, pharmaceutical companies,
health care institutions, or medical device companies may
sponsor clinical trials. Companies are required to perform
clinical trials, either to prove safety and efficacy or before
full FDA approval. Sponsoring agencies have relied on
academic investigators and institutions to design practical
protocols, assure patient enrollment, train participating in-
stitutions, and perform sophisticated data analysis. Each of
these co-ventures begins with a contractual agreement be-
tween the institution and sponsor. Institutional remuneration
for these services maintains analysts, statisticians, nurse
coordinators, and faculty salaries. When done well, clinical
trials are co-beneficial to investigators, institutions, compa-
nies, and patients. Multiple clinical trials provide a pathway
for institutional and technologic growth from patient re-
cruitment, academic publications, and financial support.
Moreover, public education elevates a center’s stature lo-
cally and nationally. A great deal of information regarding
current clinical trials may be obtained from the NIH (http://
clinicaltrials.gov/).
Conclusion: Securing Our Technologic Future
Change is difficult for established surgeons, who rely on
practices that have rendered constantly improving clinical
results in the past. However, as Cosgrove alluded in his
address, the developmental elastic modulus for many car-
diac, vascular, and thoracic surgical procedures has been
reached. Although room exists for improvement of tradi-
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tional operations and devices, now is the time for us to
spawn imaginative ideas, and develop specialty-based tech-
nology. This year the Society of Thoracic Surgeons (STS)
and the AATS co-sponsored TECHCON 2002. This con-
ference is the first in a series of society co-sponsored
conferences designed to provide the most up-to-date infor-
mation on technologic advances as they pertain to cardio-
thoracic surgery. Also, AATS/STS program committees
have made special efforts to provide state of the art tech-
nology lectures and abstract presentations in their annual
scientific programs. Ideally, these professional society ef-
forts will become a growing “tsunami,” expanding techno-
logic innovation for our specialty. Nearly 100 years after the
first air flight, the innovative spirit of the Wright brothers
comes to mind. They did the impossible with the impossi-
ble. And it all became what is now possible. The “innova-
tion imperative” is real, and cardiothoracic surgeons must
become masters of this environment to continue to opti-
mally care for our patients.
I thank Mr Walter Larkins, president of Envision Associates,
Inc, for his valuable assistance during preparation for the sympo-
sium presentation and for his review of the manuscript. He has
taught me much about technology, industry relations, and intellec-
tual property.
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